ImmunityBio Shares Gain Momentum on Strong Revenue and Regulatory Progress
02.02.2026 - 10:29:05 | boerse-global.de
ImmunityBio has entered February with significant operational momentum, driven by surging revenue, greater clarity from U.S. regulators, and initial international approvals for its immunotherapy, ANKTIVA. Following an extremely volatile January that saw shares rally over 190%, investor attention is now shifting to the next regulatory milestone: the potential speed of a planned label expansion in the United States.
The company has reported unaudited preliminary figures for its 2025 fiscal year, revealing net product revenue of approximately $113 million. This represents a staggering increase of 700% compared to the prior year.
Growth accelerated further in the fourth quarter, with revenue reaching $38.3 million. This figure marks a Read more...
So schätzen Börsenprofis die Aktie ImmunityBio ein!
Für. Immer. Kostenlos.
